this post was submitted on 22 Jun 2025

9 points (100.0% liked)

Futurology

3255 readers

104 users here now

founded 2 years ago

MODERATORS

AwesomeLowlander

9

Verve is developing a pipeline of gene editing medicines to address the drivers of atherosclerotic cardiovascular disease (ASCVD) through treatments that may only need to be given once in a lifetime. (investor.lilly.com)

submitted 2 months ago by Lugh to c/futurology

1 comments fedilink hide all child comments

you are viewing a single comment's thread
view the rest of the comments

[–] Riffraffintheroom@hexbear.net 1 points 2 months ago

That’s cool but I expect to never hear about this again ever.